Overview

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

Status:
Recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult patients with hemophilia A.

Phase:

Phase 3

Details

Lead Sponsor:

Zhengzhou Gensciences Inc

Collaborators:

Jiangsu Gensciences lnc
Jiangsu Gensciences lnc.

Treatments:

Factor VIII